@article{1484002,
      recid = {1484002},
      author = {Pant, Shubham,},
      title = {Pancreatic cancer : current therapeutics and future  directions /},
      pages = {1 online resource (vii, 196 pages) :},
      note = {Includes index.},
      abstract = {Pancreatic cancer is a challenging and complex disease  characterized by a dense fibrotic stroma and an  immunosuppressive tumor microenvironment. Until recently,  there were no predictive biomarkers to personalize  selection of targeted or biologic therapies as a part of  standard of care treatment. Moreover, the regulatory immune  population of cells creates a cold, non-immunogenic tumor  that is resistant to immunotherapies including checkpoint  inhibitors. However, in the last few years, there has been  substantial progress in our understanding of the role  mutations in the pathogenesis of disease leading to  increased adoption of germline and next generation  sequencing to identify mutations and fusions to optimize  selection of therapies and select patients for clinical  trials of targeted agents. This book provides a  comprehensive, global overview on therapy for pancreatic  cancer, exploring approved therapies and focusing on the  Next in drug development including molecularly targeted  therapy and efforts at Drugging the Undruggable: the KRAS  mutation. It also addresses efforts at targeting the  inhospitable stroma to improve drug delivery to the tumor  cells, incorporating ct DNA (liquid biopsies) in the care  of patients and recent advances in immunotherapy.  Pancreatic Cancer: Current Therapeutics and Future  Directions will illuminate these challenges, review  existing therapeutics, and highlight current and future  efforts to improve outcomes in this devastating disease.  Useful to physicians, fellows, medical students, residents,  physician assistants, nurse practitioners, pharmaceutical  companies and researchers interested in pancreatic cancer,  it will first explain management of localized disease  including resectability and adjuvant and neoadjuvant  therapies. Targeted therapies including molecular,  immunotherapy, stroma and role of ctDNA or liquid biopsies  will be addressed. Finally, the book will explore the  important role of pain management, diet and exercise in  improving outcomes in pancreatic cancer.},
      url = {http://library.usi.edu/record/1484002},
      doi = {https://doi.org/10.1007/978-3-031-38623-7},
}